Mydriatic and cycloplegic drugs: A review of ocular and systemic complications

Optometry and Vision Science

Volumn 59, Issue 2, 1982, Pages 162-177

  Rengstorff, Roy H ^a   Doughty, Cecilia B ^a  

^a US ARMY MEDICAL RESEARCH INSTITUTE OF CHEMICAL DEFENSE   (United States)

Author keywords

Adverse drug effects; Cycloplegics; Mydriatics; Ocular complications; Systemic complications

Indexed keywords

ADRENALIN; ATROPINE; CYCLOPENTOLATE; HOMATROPINE; MYDRIATIC AGENT; PHENYLEPHRINE; SCOPOLAMINE; TROPICAMIDE;

ACCOMMODATION PARALYSIS; ADVERSE DRUG REACTION; ATAXIA; CENTRAL NERVOUS SYSTEM; COMA; CONJUNCTIVITIS; CONVULSION; CORNEA PIGMENTATION; FEVER; GLAUCOMA; HEART; HEART ARRHYTHMIA; MOUTH; RETINA MACULA EDEMA; REVIEW; VISUAL IMPAIRMENT; VISUAL SYSTEM; XEROSTOMIA;

ADOLESCENT; ADULT; AGED; ATROPINE; AUTONOMIC NERVOUS SYSTEM DISEASES; CHILD; CHILD, PRESCHOOL; CYCLOPENTOLATE; EPINEPHRINE; EYE DISEASES; FEMALE; HUMAN; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGE; MYDRIATICS; PARASYMPATHOLYTICS; PHENYLEPHRINE; PIGMENTATION DISORDERS; SCOPOLAMINE; SYMPATHOMIMETICS; TROPANES; TROPICAMIDE;

EID: 0020325201     PISSN: 10405488     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006324-198202000-00008     Document Type: Article

References (148)

1. Goodman LS, Gilman A. The Pharmacological Basis of Therapeutics. 5th ed. New York: MacMillan, 1975:477-532.
2. Ellis PP. Ocular Therapeutics and Pharmacology. 5th ed. St. Louis: CV Mosby, 1977:238-244.
3. Scheie HG, Albert DM. Textbook of Ophthalmology. 9th ed. Philadelphia: WB Saunders, 1977:135-45.
4. Havener WH. Ocular Pharmacology. 4th ed. St. Louis: CV Mosby, 1978:218-61.
5. Lyle WM, Hopkins GA. The unwanted ocular effects from topical ophthalmic drugs. J Am Op-tom Assoc 1977; 48(12):1519-23.
6. Henkind P, Walsh JB, Berger AW. Physicians’ Desk Reference for Ophthalmology. Oradell, NJ: Medical Economics Co, 1978:18.
7. Henkind P, Walsh JB, Berger AW. Physicians’ Desk Reference for Ophthalmology. Oradell, NJ: Medical Economics Co, 1979.
8. Bartlett JD. Administration of and adverse reactions to cycloplegic agents. Am J Optom Physiol Opt 1978; 55:227-33.
9. Sim VM. Chemicals used as weapons in war. In: DiPalma JR, ed. Drill’s Pharmacology in Medicine. 4th ed. New York: McGraw-Hill, chap. 59, 1971:1232-48.
10. Drance SM, Ross RA. The ocular effects of epinephrine. Surv Ophthalmol 1970; 14:330-5.
11. Abraham SV. Mydriatic glaucoma—a statistical study. Arch Ophthalmol 1933; 10(6):757-62.
12. Lee PF. The influence of epinephrine and phenylephrine on intraocular pressure. Arch Ophthalmol 1958; 60:863-7.
13. Löwenstein A. Künstliche Hervorrufung Melan-otischer Geschwülstchen in der Bindehaut. Ber Dtsch Ophthalmol Ges 1927; 46:439-41.
14. Corwin ME, Spencer WH. Conjunctival melanin depositions. Arch Ophthalmol, 1963; 69:317-21.
15. Becker B, Morton WR. Topical epinephrine in glaucoma subjects. Am J Ophthalmol 1966; 62(2): 272-7.
16. Mooney D. Pigmentation after long-term topical use of adrenaline compounds. Br J Ophthalmol1970; 54:823-6.
17. Schuster H. Uber eine seltene Nebenwirkung von Adrenalin-augentropfen. Klin Monatsbl Augen-heilkd 1974; 165(3):517-9.
18. Blobner F. Hornhautverfärbung durch ein Ad-renalinprepärat. Klin Monatsbl Augenheilkd 1938; 100:758-63.
19. Reinecke RD, Kuwabara T. Corneal deposits secondary to topical epinephrine. Arch Ophthalmol 1963; 70(2):170-2.
20. Green WR, Kaufer GJ, Dubroff S. Black cornea. A complication of topical use of epinephrine. Ophthalmologica 1967; 154:88-95.
21. McCarthy RW, LeBlanc R. A black cornea secondary to topical epinephrine. Can J Ophthalmol 1976; 11:336-40.
22. Krejci L, Harrison R. Corneal pigment deposits from topically administered epinephrine; experimental production. Arch Ophthalmol 1969; 82(6): 836-9.
23. Krejci L, Harrison R. Epinephrine effects on corneal cells in tissue culture. Arch Ophthalmol1970; 83:451-4.
24. Ferry AP, Zimmerman LE. Black cornea: a complication of topical use of epinephrine. Am J Ophthalmol 1964; 58:205-10.
25. Domarus DV. Adrenochromeinlagerungen in die Komea, (“Schwarze Hornhaut”). Ophthalmologica 1977; 175:166-70.
26. Madge GE, Geeraets WJ, Guerry D. Black cornea secondary to topical epinephrine. Am J Ophthalmol 1971; 71(l):402-5.
27. Donaldson DD. Epinephrine pigmentation of the cornea. Arch Ophthalmol 1967; 78:74-5.
28. Ferry JF. Black prosthesis, a complication of the topical use of epinephrine. Am J Ophthalmol1967; 64(1):162.
29. Sugar J. Adrenochrome pigmentation of hydrophilic lenses. Arch Ophthalmol 1974; 91(1):11-2.
30. Spaeth GL. Nasolacrimal duct obstruction caused by topical epinephrine. Arch Ophthalmol1967; 77 31:355-7.
31. Barishak R, Romano A, Stein R. Obstruction of lacrimal sac caused by topical epinephrine. Ophthalmologica 1969; 159:373-9.
32. Romano A, Barishak R, Stein R. Obstruction of lacrimal puncta caused by topical epinephrine. Ophthalmologica 1973; 166:301-5.
33. Becker B. Topical epinephrine in the treatment of the glaucomas. In: Symposium on Glaucoma, New Orleans, 1966. St. Louis: CV Mosby, 1967: 152-69.
34. Kolker AE, Becker B. Epinephrine maculopathy. Arch Ophthalmol 1968; 79 51:552-62.
35. Michels RG, Maumenee AE. Cystoid macular edema associated with topically applied epinephrine in aphakic eyes. Am J Ophthalmol 1975; 80 31:379-88.
36. Obstbaum SA, Galin MA, Poole TA. Topical epinephrine and cystoid macularedema. Ann Ophthalmol 1976; 8(4):455-8.
37. Mackool RJ, Muldoon T, Fortier A, Nelson D. Epinephrine-induced cystoid macular edema in aphakic eyes. Arch Ophthalmol 1977; 95:791-3.
38. Thomas JV, Gragoudas ES, Blair NP, Lapus JV. Correlation of epinephrine use and macular edema in aphakic glaucomatous eyes. Arch Ophthalmol 1978; 96:625-8.
39. Becker B, Pettit TH, Gay AJ. Topical epinephrine therapy of open-angle glaucoma. Arch Ophthalmol 1961; 66:219-25.
40. Vaughan D, Shaffer R, Riegelman S. A new stabilized form of epinephrine for the treatment of open-angle glaucoma. Arch Ophthalmol 1961; 66:232-5.
41. Pollack IP, Rossi H. Norepinephrine in treatment of ocular hypertension and glaucoma. Arch Ophthalmol 1975; 93:173-7.
42. Waltman SR, Yarian D, Hart W, Becker B. Corneal endothelial changes with long-term topical epinephrine therapy. Arch Ophthalmol 1977; 95: 1357-8.
43. Kass MA, Stamper R, Becker B. Madarosis in chronic epinephrine therapy. Arch Ophthalmol1972; 88:429-31.
44. Byron HM. Conjunctival reaction due to 1-epinephrine bitartrate (epitrate). Arch Ophthalmol 1960; 63:567-70.
45. Ballintine EJ, Garner LL. Improvement of the coefficient of outflow in glaucomatous eyes. Arch Ophthalmol 1961; 66:314-7.
46. Alani SD, Alani MD. Allergic contact dermatitis and conjunctivitis from epinephrine. Contact Dermatitis 1976; 2(3):147-50.
47. Holland MG. Autonomic drugs in ophthalmology: some problems and promises. Section II: Anticholinergic drugs. Ann Ophthalmol 1974; 6: 661-5; Section III: Sympathomimetic drugs. 6: 875-88.
48. Keller JT. The risk of angle closure from the use of mydriatics. J Am Optom Assoc 1975; 46(1):19-21.
49. Weiss DI, Shaffer RN. Mydriatic effects of one-eighth per cent phenylephrine. Arch Ophthalmol 1962; 68:727-9.
50. Mitsui Y, Takagi Y. Nature of aqueous floaters due to sympathomimetic mydriatics. Arch Ophthalmol 1961; 65:626-31.
51. Kristensen P. Mydriasis-induced pigment liberation in the anterior chamber associated with acute rise in intraocular pressure in open-angle glaucoma. Acta Ophthalmol 1965; 43:714-24.
52. Haddad NJ, Moyer NJ, Riley FC. Mydriatic effect of phenylephrine hydrochloride. Am J Ophthalmol 1970; 70 51:729-33.
53. Aggarwal JL, Beveridge B. Liberation of iris pigment in the anterior chamber after instillation of 10% phenylephrine hydrochloride solution. Br J Ophthalmol 1971; 55(8):544-9.
54. Wang H-Z, Chen C-N. Liberation of iris pigment into the anterior chamber after instillation of phenylephrine hydrochloride. Trans Soc Ophthalmol Sin 1974; 13:40-3 (Chinese; English summary).
55. Grant WM. Toxicology of the Eye. 2nd ed. Springfield, IL: Charles C Thomas, 1974:63.
56. Kubo DJ, Wing TW, Poise KA, Jaurequi MJ. Mydriatic effects using low concentrations of phenylephrine hydrochloride. J Am Optom Assoc1975; 46 81:817-22.
57. Matilla MJ, Takki S, Idanpaan-Heikkila JE. Actions of some autonomic drugs on the human eye: experiments on medical students. Ann Med Exp Biol Fenn 1967; 45:412-6.
58. Borromeo-McGrail V, Bordiuk JM, Keitel H. Systemic hypertension following ocular administration of 10% phenylephrine in the neonate. Pediatrics 1973; 51:1032-6.
59. Cant JS. Iatrogenic eye disease. Practitioner 1969; 202:787-95.
60. Andrews IC, Belonsky BL. Parasympatholytics. Clin Anesth 1974; 10(1):ll-29.
61. Robertson DM. The eye and adverse drug effects. Some selected considerations. Minn Med 1972; 55(10):927-34, passim.
62. Gartner S, Billet E. Mydriatic glaucoma. Am J Ophthalmol 1957; 43:975-6.
63. Silverman HI. The adverse effects of commonly used systemic drugs on the human eye—Part II. Am J Optom Arch Am Acad Optom 1972; 49(4): 335-62.
64. Theodore FH. Drug sensitivities and irriations of the conjunctiva. J Am Med Assoc 1953; 151(1): 25-30.
65. Gettes BC. Three new cycloplegic drugs. Arch Ophthalmol 1954; 51:467-72.
66. Gimbel HV. The control of myopia with atropine. Can J Ophthalmol 1973; 8:527-32.
67. Christensen RE, Pearce I. Homatropine hydrobromide. Arch Ophthalmol 1963; 70:376-80.
68. Christoferson KW, Ogle KN. The effect of homatropine on the accommodation-convergence association. Arch Ophthalmol 1956; 55:779-91.
69. Fry GA. The effect of homatropine upon accom-modation/convergence relations. Am J Optom Arch Am Acad Optom 1959; 36:525-31.
70. Portney GL, Purcell TW. The influence on tro-picamide on intraocular pressure. Ann Ophthalmol 1975; 7(1):31-4.
71. Harris LS. Cycloplegic-induced intraocular pressure elevations. Arch Ophthalmol 1968; 79(3): 242-6.
72. Harris LS, Galin MA. Cycloplegic provocative testing. Arch Ophthalmol 1969; 81(4):544-7.
73. Lazenby GW, Reed JW, Grant WM. Anticholinergic medication in open-angle glaucoma. Arch Ophthalmol 1970; 84(6):719-23.
74. Mapstone R. Dilating dangerous pupils. Br J Ophthalmol 1977; 61:517-25.
75. Smith SE. Mydriatic drugs for routine fundal inspection. A reappraisal. Lancet 1971; 2:837-839.
76. Hendrickson RO, Hanna C. Use of drugs in ointment for routine mydriasis. Ann Ophthalmol1977; 9(3):333-6.
77. Aviner Z. Pupil-block; its mechanism and prevention, Part I. Ophthalmologica 1971; 163:273-7.
78. Wahl JW. Systemic reaction to tropicamide. Arch Ophthalmol 1969; 82:320-321.
79. Apt L, Henrick A. Pupillary dilation with single eyedrop mydriatic combinations. Am J Ophthalmol 1980; 89(4):553-9.
80. Scruggs J, Wallace T, Hanna C. Route of absorption of drug and ointment after application to the eye. Ann Ophthalmol 1978; 10:267-71.
81. Davidson SI. Systemic effects of eyedrops. Trans Ophthalmol Soc UK 1974; 94:487-93.
82. Lansche RK. Systemic reactions to topical epinephrine and phenylephrine. Am J Ophthalmol 1966; 61(l):95-8.
83. Howell SC. Actions of epinephrine on the normal human eye. Arch Ophthalmol 1934; 12:833-41.
84. Ballin N, Becker B, Goldman ML. Systemic effects of epinephrine applied topically to the eye. Invest Ophthalmol 1966; 5(2):125-9.
85. Dantes DA, Winkelman JW. An unusual systemic symptom-complex possibly related to absorption of eye-drops. Lancet 1972; 1:450-1.
86. Heath P, Geiter CW. Use of phenylephrine hydrochloride (Neosynephrine Hydrochloride) in ophthalmology. Arch Ophthalmol 1949; 41:172-7.
87. Hopkins GA, Lyle WM. Potential systemic side effects of six common ophthalmic drugs. J Am Optom Assoc 1977; 48(10):1241-5.
88. Matthews TG, Wilczek ZM, Shennan AT. Eye-drop induced hypertension (letter). Lancet 1977; 2(8042):827.
89. Solosko D, Smith RB. Hypertension following 10% phenylephrine ophthalmic. Anesthesiology1972; 36:187-9.
90. Wilensky JT, Woodward HJ. Acute systemic hypertension after conjunctival instillation of phenylephrine hydrochloride. Am J Ophthalmol 1973; 76(l):156-7.
91. Fraunfelder FT, Scafidi AF. Possible adverse effects from topical ocular 10% phenylephrine. Am J Ophthalmol 1978; 85(4):447-53.
92. Keller JT, Chang FW. An evaluation of the use of topical anesthetics and low concentrations of phenylephrine HC1 for mydriasis. J Am Optom Assoc 1976; 47(6):752-4.
93. McReynolds WU, Havener WH, Henderson JW. Hazards of the use of sympathomimetic drugs in ophthalmology. Arch Ophthalmol 1956; 56(2): 176-9.
94. Ellis PP. Systemic reactions to topical therapy. Int Ophthalmol Clin 1971; 11(2):1-11.
95. Vaughan RW. Ventricular arrhythmias after topical vasoconstrictors. Anesth Analg (Cleve) 1973; 52(2):161-5.
96. Samantary S, Thomas A. Systemic effects of topical phenylephrine. Indian J Ophthalmol1975; 23(1): 16-7.
97. Abramowicz M, ed. Adverse systemic effects from topical eye drugs. Med Lett Drugs Ther 1973; 15(5):23-4.
98. Abramowicz M, Babies blood pressure raised by eye drops (Editorial). Br Med J 1974; l(5896):2-3.
99. Kim JM, Stevenson CE, Mathewson HS. Hypertensive reactions to phenylephrine eyedrops in patients with sympathetic denervation. Am J Ophthalmol 1978; 85:862-8.
100. Robertson D. Contraindications to the use of ocular phenylephrine in idiopathic orthostatic hypotension. Am J Ophthalmol 1979; 87:819-22.
101. Yolton DP, Kandel JS, Yolton RL. Diagnostic pharmaceutical agents: side effects encountered in a study of 15,000 applications. J Am Optom Assoc 1980; 51(2):113-7.
102. Brown MM, Brown GC, Spaeth GL. Lack of side effects from topically administered 10% phenylephrine eyedrops. A controlled study. Arch Ophthalmol 1980; 98(3):487-9.
103. Shader RI, Greenblatt DJ. Uses and toxicity of belladonna alkaloids and synthetic anticholinergics. Semin Psychiatry 1971; 3(14):449-76.
104. Tyson WJ. Toxic effects of atropine drops. Br Med J 1889; 2:921.
105. Owens SM. Two cases of atropine poisoning. Lancet 1890; 2:443.
106. Kelynack TN. Atropine poisoning by absorption from the conjunctiva. Br Med J 1890; 1:421.
107. Harris WJ. Case of rapid development of symptoms of belladonna poisoning from use of sulphate of atropine eyedrops. Lancet 1898; 1:98.
108. Spurgin PB. Two cases of poisoning from application of atropine to the eyes. Lancet 1905; 2:964.
109. Baker JP, Farley JD. Toxic psychosis following atropine eye-drops. Br Med J 1958; 2:1390-2.
110. Kounis RG. Atropine eye-drops delirium (letter). Can Med Assoc J 1974; 110(7):759.
111. Letson RD. The use of drugs in the management of strabismus. Surv Ophthalmol 1970; 14(5):424-32.
112. Rockcliffe WC. Notes on death supposed to be from atropine drops applied to the eye. Trans Ophthalmol Soc UK 1902; 22:302-4.
113. Morton HG. Atropine intoxication: its manifestations in infants and children. J Pediatr 1939; 14: 755-60.
114. Heath WE. Death from atropine poisoning. Br Med J 1950; 2:608.
115. Duke PS. Ocular side effects of drug therapy. Med J Aust 1967; 1:927-9.
116. Lubeck MJ. Effects of drugs on ocular muscles. Int Ophthalmol Clin 1971; 2(2):35-62.
117. Hoefnagel D. Toxic effects of atropine and hom-atropine eyedrops in children. N Engl J Med 1961; 264(4):168-71.
118. German E, Siddiqui N. Atropine toxicity from eyedrops (letter). N Engl J Med 1970; 282(12): 689.
119. Doden W. Intoxikation durch atropin-Augen-tropfen. Dtsch Med Wochenschr 1972; 97(6):212.
120. Janssen F. Condilium—Leserbriefe. Paediatr Paedol 1973; 8:104.
121. Schäfer WD, Sauerland HJ. Beobachtungen nach Atropin-Langzeit Verordnung. Klin Mon-atsbl Augenheilk 1976; 168(3):421-3.
122. Sampson WG. Role of cycloplegia in the management of functional myopia. Ophthalmology 1979; 86(5):695-7.
123. Bedrossian RH. The effect of atropine on myopia. Ophthalmology 1979; 86(5);713-9.
124. Dyer JA. Role of cycloplegics in progressive myopia. Ophthalmology 1979; 86(5):692-4.
125. Freund M, Merin S. Toxic effects of scopolamine eye drops. Am J Ophthalmol 1970; 70(4):637-9.
126. Krynyckyj V, Janovsky F, Sedivec V. Intoxikacni psychöza po nakapâni skopolaminu do spojivko-vého vaku. Cesk Psychiatr 1966; 62(6):405-8.
127. Walsh FB, Hoyt WF. Clinical Neuro-Ophthalmology. 3rd ed. Baltimore: Williams and Wilkins, 1969:1380-5.
128. Walsh FB. Clinical Neuro-Ophthalmology. 2nd ed. Baltimore: Williams and Wilkins, 1957:1294.
129. Home GO. Sensitivity to atropine in anhidrotic heat exhaustion. Trans R Soc Trop Med Hyg1954; 48:153-5.
130. Jahnke W. Atropinvergiftigungen im heissenKlima. Arch Toxikol 1957; 16:243-7.
131. Simcoe CW. Cyclopentolate (Cyclogyl) toxicity. Arch Ophthalmol 1962; 67:406-8.
132. Beswick JA. Psychosis from cyclopentolate. Am J Ophthalmol 1962; 53(5):879-80.
133. Binkhorst RD, Weinstein GW, Baretz C, Clahane AC. Psychotic reactions inducted by cyclopentolate (Cyclogyl). Am J Ophthalmol 1963; 55(6): 1243-5.
134. Praeger DL, Miller SN. Toxic effects of cyclopentolate (Cyclogel). Am J Ophthalmol 1964; 58: 1060-1.
135. Schmidt I. Two patients with unusual reaction to drugs used in optométrie practice. Am J Optom Arch Am Acad Optom 1970; 47(4):312.
136. Kennerdell JS, Wucher FP. Cyclopentolate associated with two cases of grand mal seizure. Arch Ophthalmol 1972; 87(6):634-5.
137. Bauer CR, Trottier MCT, Stern L. Systemic cyclopentolate (Cyclogyl) toxicity in the newborn infant. J Pediatr 1973; 82(3):501-5.
138. Adcock EW. Cyclopentolate (Cyclogyl) toxicity in pediatric patients. J Pediatr 1971; 79(1): 127-9.
139. Mark HH. Psychotogenic properties of cyclopentolate. J Am Med Assoc 1963; 186(4):430-1.
140. A wan KJ. Systemic toxicity of cyclopentolate hydrochloride in adults following topical ocular instillation. Ann Ophthalmol 1976; 8(7):803.
141. Awan KJ. Adverse systemic reactions of topical cyclopentolate hydrochloride. Ann Ophthalmol1976; 8(6):695-8.
142. Missiroli A. Effetti tossici del ciclopentolato, su di un caso di disartria grave con perdita transi-toria della fonazione. Boll Oculist 1969; 48:433
143. Carpenter WT. Precipitous mental deterioration following cycloplegia with 0.2% cyclopentolate HC1. Arch Ophthalmol 1967; 78(4):445-7.
144. Hill K. Systemic reactions to tropicamide (Letter). Arch Ophthalmol 1970; 83:382.
145. Rogell GD. Systemic reactions to tropicamide (Letter). Arch Ophthalmol 1970; 83:382-3.
146. Garston MJ. A closer look at diagnostic drugs for optométrie use. J Am Optom Assoc 1975; 46(1): 39-43.
147. Ostler HB. Cycloplegics and mydriatics: tolerance, habituation, and addiction to topical administration. Arch Ophthalmol 1975; 93(6):432
148. Forman AR. A new low-concentration preparation for mydriasis and cycloplegia. Ophthalmology 1980; 87(3):213-5.